Amgen Inc. $AMGN Shares Acquired by Perpetual Ltd

Perpetual Ltd boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 54.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,502 shares of the medical research company’s stock after purchasing an additional 1,595 shares during the quarter. Perpetual Ltd’s holdings in Amgen were worth $1,474,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock valued at $15,204,047,000 after buying an additional 165,281 shares during the period. State Street Corp increased its holdings in shares of Amgen by 0.6% during the 2nd quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock worth $8,196,775,000 after buying an additional 177,035 shares during the last quarter. Capital International Investors increased its holdings in shares of Amgen by 1.5% during the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after buying an additional 282,219 shares during the last quarter. Capital World Investors boosted its holdings in Amgen by 11.5% in the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after acquiring an additional 1,935,876 shares during the last quarter. Finally, Capital Research Global Investors boosted its holdings in Amgen by 2.7% in the third quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company’s stock valued at $1,335,168,000 after acquiring an additional 122,631 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on AMGN shares. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Piper Sandler raised their price objective on Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Freedom Capital lowered Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. Wells Fargo & Company boosted their target price on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Finally, Jefferies Financial Group initiated coverage on shares of Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and an average target price of $354.60.

Amgen Price Performance

AMGN opened at $347.94 on Friday. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The firm has a market cap of $187.56 billion, a price-to-earnings ratio of 24.45, a PEG ratio of 3.45 and a beta of 0.47. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The company has a fifty day simple moving average of $363.65 and a 200 day simple moving average of $332.77.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. Amgen’s payout ratio is 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.